Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kieran F Docherty

Showing results (131-140 of 143) with videos related to

Pageof 15
Sort By:
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
European Journal of Heart Failure|March 2, 2026
SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart FailureRoss T Campbell, Joanna Osmanska, Kieran F Docherty, et al.
JACC. Heart Failure|March 7, 2023
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction SpectrumJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
JAMA|November 7, 2025
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-AnalysisNatalie Staplin, Alistair J Roddick, Brendon L Neuen, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Circulation|July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFAlice M Jackson, Pooja Dewan, Inder S Anand, et al.
Pageof 15

Showing results (131-140 of 143) with videos related to

Sort By:
Pageof 15
Circulation|October 12, 2020
Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HFPardeep S Jhund, Scott D Solomon, Kieran F Docherty, et al.
Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.
Circulation|September 5, 2020
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HFKieran F Docherty, Pardeep S Jhund, Inder Anand, et al.
European Journal of Heart Failure|March 2, 2026
SUBCUT HF II: rationale and design of a multicentre randomized controlled trial of SUBCUTaneous furosemide to support early discharge in patients admitted to hospital due to Heart FailureRoss T Campbell, Joanna Osmanska, Kieran F Docherty, et al.
JACC. Heart Failure|March 7, 2023
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction SpectrumJawad H Butt, Kieran F Docherty, Brian L Claggett, et al.
JAMA|November 7, 2025
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-AnalysisNatalie Staplin, Alistair J Roddick, Brendon L Neuen, et al.
Circulation|November 13, 2020
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)Matthew M Y Lee, Katriona J M Brooksbank, Kirsty Wetherall, et al.
European Heart Journal|August 22, 2020
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)Matteo Serenelli, Michael Böhm, Silvio E Inzucchi, et al.
JAMA|November 7, 2025
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-AnalysisBrendon L Neuen, Robert A Fletcher, Stefan D Anker, et al.
Circulation|July 17, 2020
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HFAlice M Jackson, Pooja Dewan, Inder S Anand, et al.
Pageof 15